Immunic secures $400M to support late-stage MS trials - ICYMI

robot
Abstract generation in progress

Immunic Inc. has secured up to $400 million in a private placement to fund late-stage clinical trials for vidofludimus calcium in multiple sclerosis and prepare for its commercial launch. CEO Dr. Daniel Vitt described the financing as transformative, noting that $200 million has already been received. The funds will support the completion of the Phase 3 ENSURE program in relapsing MS and allow the company to initiate a Phase 3 study in primary progressive MS.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)